Xeltis announced today that it completed enrollment in an EU pivotal trial for aXess, its restorative vascular access conduit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback